DE69918146D1 - Verfahren zur therapeutischen impfung - Google Patents

Verfahren zur therapeutischen impfung

Info

Publication number
DE69918146D1
DE69918146D1 DE69918146T DE69918146T DE69918146D1 DE 69918146 D1 DE69918146 D1 DE 69918146D1 DE 69918146 T DE69918146 T DE 69918146T DE 69918146 T DE69918146 T DE 69918146T DE 69918146 D1 DE69918146 D1 DE 69918146D1
Authority
DE
Germany
Prior art keywords
antigen
weak
analogues
antigens
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918146T
Other languages
English (en)
Other versions
DE69918146T2 (de
Inventor
Lucilla Steinaa
Soren Mouritsen
Gregorius Nielsen
Jesper Haaning
Dana Leach
Iben Dalum
Anand Gautam
Birk Peter Rasmussen
Gunilla Karlsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BN ImmunoTherapeutics Inc
Original Assignee
Affitech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69918146(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Affitech AS filed Critical Affitech AS
Publication of DE69918146D1 publication Critical patent/DE69918146D1/de
Application granted granted Critical
Publication of DE69918146T2 publication Critical patent/DE69918146T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69918146T 1998-10-05 1999-10-05 Verfahren zur therapeutischen impfung Expired - Lifetime DE69918146T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK126198 1998-10-05
DKPA199801261 1998-10-05
US10501198P 1998-10-20 1998-10-20
US105011P 1998-10-20
PCT/DK1999/000525 WO2000020027A2 (en) 1998-10-05 1999-10-05 Methods for therapeutic vaccination

Publications (2)

Publication Number Publication Date
DE69918146D1 true DE69918146D1 (de) 2004-07-22
DE69918146T2 DE69918146T2 (de) 2005-07-07

Family

ID=26065489

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918146T Expired - Lifetime DE69918146T2 (de) 1998-10-05 1999-10-05 Verfahren zur therapeutischen impfung

Country Status (25)

Country Link
US (3) US7005498B1 (de)
EP (1) EP1117421B2 (de)
JP (1) JP2002526419A (de)
KR (1) KR100731820B1 (de)
CN (1) CN1325115C (de)
AT (1) ATE269100T1 (de)
AU (1) AU751709B2 (de)
CA (1) CA2345817C (de)
CZ (1) CZ20011049A3 (de)
DE (1) DE69918146T2 (de)
EA (1) EA003634B1 (de)
EE (1) EE200100203A (de)
ES (1) ES2222728T3 (de)
HK (1) HK1039749B (de)
HR (1) HRP20010319A2 (de)
HU (1) HUP0103976A3 (de)
IL (1) IL141868A0 (de)
MX (1) MXPA01003503A (de)
NO (1) NO20011586L (de)
NZ (1) NZ511055A (de)
PL (1) PL202399B1 (de)
PT (1) PT1117421E (de)
SK (1) SK4272001A3 (de)
TR (1) TR200100936T2 (de)
WO (1) WO2000020027A2 (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0866805A1 (de) 1995-12-12 1998-09-30 Karolinska Innovations AB Peptide, das die KLVFF Sequenz von beta-Amyloid bindet
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
NZ511055A (en) 1998-10-05 2003-10-31 Pharmexa As Novel methods for therapeutic vaccination
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
EE200100552A (et) * 1999-04-23 2002-12-16 Pharmexa A/S Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
ATE418340T1 (de) * 1999-05-06 2009-01-15 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
KR100879810B1 (ko) * 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 아밀로이드의 하향-조절을 위한 신규한 방법
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
AU2001285721A1 (en) * 2000-09-06 2002-03-22 Pharmexa A/S Method for down-regulating IgE
WO2002034287A2 (en) * 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
AU2002233166B2 (en) * 2001-02-19 2006-06-29 Pharmexa A/S Synthetic vaccines comprising polyhydroxypolymer carriers
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
WO2003015716A2 (en) 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
EP1467751A2 (de) * 2002-01-17 2004-10-20 Pharmexa A/S Immunogenes cea
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
CA2513044A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PL377028A1 (pl) * 2002-03-26 2006-01-23 Immunex Corporation Sposoby wykorzystania ligandu Flt-3 w procedurach immunizacyjnych
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
EP2426139B1 (de) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4-Antagonisten und Verwendung davon
GB0228796D0 (en) * 2002-12-11 2003-01-15 Adjuvantix Ltd Valency
SE0301109D0 (sv) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
EP2365001A3 (de) * 2003-05-01 2012-03-28 Imclone LLC Vollständig humane Antikörper, die sich gegen den Wachstumfaktor-1-Rezeptor richten, der dem menschlichen Insulin ähnelt
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
DE602004020769D1 (de) 2003-06-25 2009-06-04 Bn Immunotherapeutics Inc Aufreinigung von her-2-varianten
US7763452B2 (en) 2003-06-25 2010-07-27 Bn Immunotherapeutics, Inc. Purification of HER-2 variants
JP5097400B2 (ja) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． 複合ワクチン
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
US20070184023A1 (en) * 2003-10-30 2007-08-09 Pharmexa A/S Method for down-regulation of vegf
AU2003290460A1 (en) * 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
AU2006228872A1 (en) * 2005-03-31 2006-10-05 Pharmexa A/S Immunogenic EGFR peptides comprising foreign Tcell stimulating epitope
CN100354002C (zh) * 2005-05-31 2007-12-12 中国人民解放军第三军医大学第一附属医院 一种新的以异种免疫细胞为细胞载体的细胞疫苗及其制备方法
WO2006138567A2 (en) * 2005-06-17 2006-12-28 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
ES2452115T3 (es) * 2005-06-17 2014-03-31 Imclone Llc Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
AP2008004569A0 (en) * 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
EP1989227A2 (de) * 2006-02-09 2008-11-12 Transtech Pharma, Inc. Rage-fusionsproteine und anwendungsverfahren
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CA2651348A1 (en) * 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
WO2007137586A2 (en) * 2006-05-31 2007-12-06 Pharmexa A/S Random insertion of peptides
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008045346A2 (en) 2006-10-06 2008-04-17 Bn Immunotherapeutics Inc. Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer
US20100184694A1 (en) 2006-12-21 2010-07-22 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
EP2134830A2 (de) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oszillations-zellkultur-bioreaktor
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
EP2155782A2 (de) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc-peptid-komplexe und anwendungen davon bei infektionskrankheiten
US20090074828A1 (en) * 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
WO2009023266A1 (en) * 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members
BRPI0817108B8 (pt) 2007-09-21 2021-05-25 Univ California composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.
EP2197908A2 (de) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009052328A1 (en) * 2007-10-18 2009-04-23 Bn Immunotherapeutics Inc. Use of mva to treat prostate cancer
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
EP2367567A4 (de) * 2008-08-05 2014-12-03 Univ Queensland Gerüste mit antigenen
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US7998488B2 (en) * 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
AU2010232512B2 (en) 2009-04-01 2013-07-18 University Of Miami Vaccine compositions and methods of use thereof
EP3611270B1 (de) * 2009-05-19 2021-12-01 University Of Miami Kits zur in-vitro-antigen-darstellung, zur überprüfung der wirksamkeit eines impfstoffs und zur überprüfung der immuntoxizität von biologischen stoffen und arzneimitteln
MX2011013459A (es) 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Terapia de peptido para incrementar los niveles de plaquetas.
EP2448593B1 (de) 2009-07-03 2020-11-25 Bionor Immuno AS Kombination oder fusion aus hiv-peptiden zur verwendung für hiv-imfpstoffzusammensetzungen oder als diagnostikum
AU2010293059B2 (en) * 2009-08-26 2017-03-16 Selecta Biosciences, Inc. Compositions that induce T cell help
JP2013504600A (ja) * 2009-09-14 2013-02-07 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ＩＬ−１５受容体αおよび／またはそれをコードする核酸分子を含むワクチンおよび免疫治療薬、ならびにそれを用いる方法
US10706955B2 (en) * 2010-03-23 2020-07-07 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2011130249A2 (en) * 2010-04-13 2011-10-20 Immunovative Therapies, Ltd. Methods and compositions for inhibition of treg cells
EA201500857A1 (ru) 2010-05-26 2016-06-30 Селекта Байосайенсиз, Инк. Комбинированные вакцины с синтетическими наноносителями
EP2640190A4 (de) 2010-11-05 2016-05-11 Selecta Biosciences Inc Modifizierte nikotinische verbindungen und zugehörige verfahren
JP6077450B2 (ja) * 2010-11-12 2017-02-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途
MX346475B (es) 2011-01-06 2017-03-22 Bionor Immuno As Peptidos inmunogenicos monomericos y multimericos.
CN102716472A (zh) * 2011-03-31 2012-10-10 李光辉 一种肿瘤疫苗及其合成方法
BR112013027508A2 (pt) 2011-04-29 2017-03-14 Selecta Biosciences Inc nanotransportadores sintéticos tolerogênicos para reduzir respostas de anticorpos
SG10202012534VA (en) * 2011-05-26 2021-01-28 Geneius Biotechnology Inc Modulated Immunodominance Therapy
EA201490381A1 (ru) 2011-07-29 2014-06-30 Селекта Байосайенсиз, Инк. Синтетические наноносители, которые стимулируют формирование гуморального иммунного ответа и иммунного ответа, опосредованного цитотоксическими т-лимфоцитами (ctl)
WO2013040015A2 (en) * 2011-09-13 2013-03-21 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN103063836B (zh) * 2011-10-18 2016-03-30 复旦大学附属华山医院 检测分枝杆菌感染的试剂、方法和试剂盒
WO2013123424A1 (en) 2012-02-17 2013-08-22 Mayo Foundation For Medical Education And Research Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
CN104619718A (zh) 2012-06-06 2015-05-13 比奥诺尔免疫有限公司 源自病毒蛋白的肽用作免疫原和配药成分
MX2014014668A (es) 2012-06-06 2015-03-19 Bionor Immuno As Vacuna.
PL2895600T3 (pl) 2012-09-11 2020-10-05 Oncotherapy Science, Inc. Peptydy UBE2T i szczepionki je zawierające
WO2014062778A1 (en) 2012-10-19 2014-04-24 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
JP6431484B2 (ja) * 2012-12-28 2018-11-28 セルスティス リミテッド 細胞媒介免疫応答アッセイ
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
EP3142689B1 (de) 2014-05-13 2020-11-11 Bavarian Nordic A/S Kombinationstherapie gegen krebs mit einem ein-krebsantigen-exprimierenden poxvirus und einem monoklonalen antikörper gegen tim-3
WO2016005508A1 (en) 2014-07-11 2016-01-14 Bionor Immuno As Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
US20210260181A1 (en) * 2014-09-16 2021-08-26 Altimmune, Inc Coronavirus immunogenic compositions and uses thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CA3016420A1 (en) * 2015-03-11 2016-09-15 Board Of Regents Of The University Of Nebraska Conformationally stable analogs of the response selective c5a agonist ep67
AU2016235388B2 (en) * 2015-03-20 2022-02-03 Children's National Medical Center Generating virus or other antigen-specific T cells from a naive T cell population
WO2016177833A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
ES2809508T3 (es) * 2015-10-06 2021-03-04 Invectys Estructuras artificiales de poliepítopos para uso en inmunoterapia
EP3419645B1 (de) 2016-02-23 2020-09-02 BioLineRx Ltd. Verfahren zur festlegung eines behandlungsplans für akute myeloische leukämie
CN105879058B (zh) * 2016-05-10 2017-11-14 华中科技大学 一种结核病基因药物及其制备方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
EP3784688A2 (de) 2018-04-26 2021-03-03 Agenus Inc. Hitzeschockproteinbindende peptidzusammensetzungen und verfahren zu deren verwendung
WO2020070303A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
CN111068069B (zh) * 2018-10-18 2022-05-20 中国医学科学院药物研究所 一种免疫靶向功能性脂质体及其制备方法与用途
AU2019385665A1 (en) 2018-11-20 2021-05-27 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40l
US20230190922A1 (en) 2019-11-20 2023-06-22 Bavarian Nordic A/S Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
IL295548A (en) * 2020-02-14 2022-10-01 Altimmune Inc Immunogenic compositions of the corona virus and their uses
CN112980857A (zh) * 2021-04-26 2021-06-18 重庆医科大学附属儿童医院 一种编码分泌性野生型gaa蛋白的核苷酸组合物、腺相关病毒载体及其药物和应用
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
EP4452306A1 (de) 2021-12-23 2024-10-30 Bavarian Nordic A/S Therapie zur modulierung der immunantwort mit rekombinantem mva zur il-12-codierung
WO2024121411A1 (en) * 2022-12-09 2024-06-13 Strike Pharma Ab Optimized tag moiety
WO2024149832A1 (en) 2023-01-12 2024-07-18 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0224574A4 (de) 1985-06-04 1988-04-26 Biotech Res Partners Ltd Autoantigene impfstoffe.
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US5126399A (en) * 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
CA2006700A1 (en) * 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
US5501063A (en) 1994-09-06 1996-03-26 Kimberly-Clark Corporation Apparatus and method of reducing the force to expel a tampon from a tampon applicator and the applicator itself
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
CA2250428A1 (en) 1996-05-01 1997-11-06 T Cell Sciences, Inc. Plasmid-based vaccine for treating atherosclerosis
EP0951559A1 (de) * 1996-07-25 1999-10-27 Therion Biologics Corporation Rekombinantes pockenvirus für die immunisierung gegen tumor-assoziierte antigene
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
EP0959893A4 (de) * 1996-12-10 2004-11-10 Sloan Kettering Institutefor C Stimulierung einer immunantwort auf ein differentiationsantigen, das durch ein verändertes antigen stimuliert wird
AU724294B2 (en) 1997-01-22 2000-09-14 Eisai Inc. Microparticles for delivery of nucleic acid
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
HU228467B1 (en) 1998-02-05 2013-03-28 Smithkline Beecham Biolog Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
AU4600399A (en) 1998-04-30 1999-11-23 Lisa Schneider Machine tool with tool changeout
NZ511055A (en) * 1998-10-05 2003-10-31 Pharmexa As Novel methods for therapeutic vaccination

Also Published As

Publication number Publication date
EA200100425A1 (ru) 2001-10-22
SK4272001A3 (en) 2003-02-04
MXPA01003503A (es) 2005-01-14
PT1117421E (pt) 2004-11-30
US7807441B2 (en) 2010-10-05
PL347977A1 (en) 2002-05-06
EP1117421B1 (de) 2004-06-16
HK1039749B (zh) 2007-10-05
DE69918146T2 (de) 2005-07-07
EE200100203A (et) 2002-10-15
KR100731820B1 (ko) 2007-06-25
ATE269100T1 (de) 2004-07-15
US20040141958A1 (en) 2004-07-22
NO20011586D0 (no) 2001-03-28
US20060008465A1 (en) 2006-01-12
EP1117421A2 (de) 2001-07-25
WO2000020027A3 (en) 2000-10-12
AU5851099A (en) 2000-04-26
NO20011586L (no) 2001-05-31
KR20010085894A (ko) 2001-09-07
IL141868A0 (en) 2002-03-10
WO2000020027A2 (en) 2000-04-13
TR200100936T2 (tr) 2001-08-21
CN1323217A (zh) 2001-11-21
CN1325115C (zh) 2007-07-11
ES2222728T3 (es) 2005-02-01
EP1117421B2 (de) 2014-03-19
NZ511055A (en) 2003-10-31
CA2345817C (en) 2013-02-12
PL202399B1 (pl) 2009-06-30
HUP0103976A2 (hu) 2002-02-28
HK1039749A1 (en) 2002-05-10
EA003634B1 (ru) 2003-08-28
AU751709B2 (en) 2002-08-22
CA2345817A1 (en) 2000-04-13
US7005498B1 (en) 2006-02-28
JP2002526419A (ja) 2002-08-20
US7820633B2 (en) 2010-10-26
HUP0103976A3 (en) 2008-04-28
HRP20010319A2 (en) 2002-06-30
CZ20011049A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
DE69918146D1 (de) Verfahren zur therapeutischen impfung
BR9306984A (pt) Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
ME00183B (me) Novi postupak za deregulaciju amiloida
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
ATE411043T1 (de) Verfahren von dna-impfung
BRPI9912177B8 (pt) epítopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptídeo sintéticos, imunógenos de peptídeo e método para a produção dos mesmos
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
DE60325696D1 (de) Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
HK1093314A1 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
DK0880360T3 (da) Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
ATE346931T1 (de) Clostridium perfringens impfstoff
TNSN08184A1 (en) Chimeric antigens and vaccines
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
SE9903534D0 (sv) Vaccin
EP1502602A3 (de) Verfahren zur therapeutischen Impfung
BR9709993A (pt) Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica
YU24401A (sh) Novi postupci za terapeutsku vakcinaciju
DK1146889T3 (da) Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407
ATE374622T1 (de) Genetische impstoffe mit adjuvans
GB201015223D0 (en) Vaccines
BR0009746A (pt) Molécula de veìculo, composição imunogênica, polipeptìdeo, método para tratar um indivìduo, e, plasmìdeos pebl1-pv e pviii
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor
RAHMAN et al. CROSS-PROTECTION INDUCED BY CROSS-REACTIVE ANTIGEN AGAINST FASCIOLA GlGANTlCA AND TRICHINEL LA SPlRA LlS INFECTIONS

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: BN IMMUNOTHERAPEUTICS, INC., MOUNTAIN VIEW, CA, US